Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$3.14 USD
-0.08 (-2.48%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $3.17 +0.03 (0.96%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NERV 3.14 -0.08(-2.48%)
Will NERV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NERV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NERV
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
NERV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Other News for NERV
Minerva Neurosciences Announces Board and Audit Committee Changes
Minerva price target lowered by $4 at H.C. Wainwright, here's why
NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024
Minerva Neurosciences: Q1 Earnings Snapshot
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates